Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Financials
52W LOW $23.6252W HIGH $30.44
Volume
25.30 M
Value Traded
1.34 B
Short % Float
2.64%
Days to Cover
4.4
+1.19%Week
+3.73%1 Month
+20.75%3 Month
+11.2%6 Month
-35.59%5 Year
+5,929.79%All Time
Cash Data
- Cash FlowProfitable
- SEC Filing
Key Stats
Market Cap
169.79 B
EPS (TTM)
0.76
P/E Ratio
39.19
Ent. Value
221.22 B
Total Shares
5.70 B
Float Shares
5.69 B
Insiders
0.09%
Institutions
69.71%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
PFE Catalyst Timeline
Dated clinical, regulatory and corporate events for Pfizer, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Pfizer, Inc.
441Total events
39Upcoming
191Tier-1 (high impact)
2014 to 2031Coverage
Upcoming catalysts 2
Event history 50
▲Oral PresentationPF-07872412Presentation
Detailed Phase 2 results for 25vPnC presented orally at IDWeek 2026
invasive pneumococcal disease (IPD) preventionsource ↗
▲Full ResultsPF-07872412Clinical Data
Detailed Phase 2 immunogenicity/safety results across 25 serotypes for 25vPnC
invasive pneumococcal disease (IPD) preventionsource ↗
▲Partnership / LicenseCorporate
Enodia enters research collaboration and license agreement with Pfizer for Sec61 inhibitors
▲FDA ApprovalTUKYSAApprovedFDA Decision
FDA approves TUKYSA with trastuzumab and pertuzumab as front-line maintenance for HER2+ metastatic breast cancer
HER2+ metastatic breast cancer (front-line maintenance)source ↗
▲Corporate ApprovalCorporate
Pfizer board declares fourth-quarter 2026 dividend of $0.43 per share
▲Topline ReadoutRitlecitinibApprovedClinical Data
LITFULO 100 mg met co-primary endpoints in TRANQUILLO 2 at Week 52
nonsegmental vitiligosource ↗
▲Oral PresentationRitlecitinibApprovedPresentation
Late-breaking oral presentation of TRANQUILLO 2 and TRANQUILLO results at EADV 2026
nonsegmental vitiligosource ↗
●Additional DataCibinqoApprovedClinical Data
Late-breaking exploratory serum protein biomarker analysis from JADE COMPARE
atopic dermatitissource ↗
●Safety Data UpdateCibinqoApprovedClinical Data
Final integrated safety analysis of CIBINQO in 3,850 patients with up to 6.5 years exposure
atopic dermatitissource ↗
▲Primary Endpoint MetRitlecitinibApprovedClinical Data
TRANQUILLO 2 co-primary endpoints met
nonsegmental vitiligosource ↗
●Interim Efficacy Datatilrekimig and rHuPH20Clinical Data
Interim Phase 2 Week 16 efficacy and safety results for tilrekimig (PF-07275315)
atopic dermatitissource ↗
▲Long Term DataRitlecitinibApprovedClinical Data
Long-term Phase 3 data showing scalp hair regrowth with LITFULO through five years
alopecia areatasource ↗
▲Oral Presentationtilrekimig and rHuPH20Presentation
Detailed Phase 2 results presented in oral presentation at EADV Annual Congress
moderate-to-severe atopic dermatitissource ↗
▲Safety Data Updatetilrekimig and rHuPH20Clinical Data
Safety data from Phase 2 study showing tilrekimig well-tolerated
moderate-to-severe atopic dermatitissource ↗
▲Primary Endpoint Mettilrekimig and rHuPH20Clinical Data
Phase 2 study met primary endpoint of EASI-75 at Week 16 in atopic dermatitis
moderate-to-severe atopic dermatitissource ↗
▲Secondary Endpoint Datatilrekimig and rHuPH20Clinical Data
Key secondary endpoint vIGA 0/1 results at Week 16
moderate-to-severe atopic dermatitissource ↗
▲Additional Datatilrekimig and rHuPH20Clinical Data
Exploratory PP-NRS4 itch reduction analysis
moderate-to-severe atopic dermatitissource ↗
●Management ChangeCorporate
Professor Bill Sessa appointed Chair of Isomab's Scientific Advisory Board
▲Supplemental ApprovalComirnatyApprovedFDA Decision
FDA approved sBLA for COMIRNATY XFG-adapted COVID-19 vaccine
COVID-19source ↗
▲Product LaunchComirnatyApprovedPost-Market
Shipping of 2026-2027 COVID-19 vaccine begins immediately
COVID-19source ↗
●IP Litigation RulingProveraApprovedIP / Competition
Court issues case-management order noting settlement
intracranial meningiomassource ↗
●EU MAA SubmissionPF-07307405Ex-US Regulatory
EMA review of LB6V Lyme vaccine MAA initiated
Lyme diseasesource ↗
▲Topline ReadoutHYMPAVZIApprovedClinical Data
Positive topline results from Phase 3 BASIS study
hemophilia A or B with inhibitorssource ↗
▲Primary Endpoint MetHYMPAVZIApprovedClinical Data
Primary endpoint met in BASIS study
hemophilia A or B with inhibitorssource ↗
▲Topline ReadoutRitlecitinibApprovedClinical Data
Positive topline Phase 3 results for LITFULO in nonsegmental vitiligo (TRANQUILLO 2)
nonsegmental vitiligosource ↗
▲Primary Endpoint MetRitlecitinibApprovedClinical Data
TRANQUILLO met co-primary endpoints (F-VASI75 and T-VASI50 at Week 52)
nonsegmental vitiligosource ↗
●Safety Data UpdateRitlecitinibApprovedClinical Data
Safety profile consistent with alopecia areata; no new safety signals in NSV
nonsegmental vitiligosource ↗
▲CHMP Positive OpinionEx-US Regulatory
CHMP recommends marketing authorization for LP.8.1-adapted monovalent COVID-19 vaccine
COVID-19source ↗
▲CHMP Positive OpinionCOMIRNATY®LP.8.1Ex-US Regulatory
CHMP recommended marketing authorization for LP.8.1-adapted COVID-19 vaccine
COVID-19source ↗
▲EU ApprovalComirnatyApprovedEx-US Regulatory
European Commission grants marketing authorization for XFG-adapted COVID-19 vaccine
COVID-19 preventionsource ↗
▲CHMP Positive OpinionComirnatyApprovedEx-US Regulatory
CHMP recommends XFG-adapted COVID-19 vaccine
COVID-19 preventionsource ↗
▲FDA Filing AcceptedTALZENNAApprovedRegulatory Filing
FDA accepted sNDA for TALZENNA plus XTANDI for mCSPC
HRR gene-mutated metastatic castration-sensitive prostate cancersource ↗
▲Partnership / LicenseCorporate
Bluesight and Pfizer partner to integrate SmartDose RFID-enabled medications with KitCheck
●IP Litigation RulingProveraApprovedIP / Competition
Pfizer enters settlement program for Depo-Provera litigation
intracranial meningiomassource ↗
▲FDA ApprovalPADCEVApprovedFDA Decision
FDA approves PADCEV plus Keytruda as neoadjuvant and adjuvant treatment for muscle-invasive bladder cancer
muscle-invasive bladder cancersource ↗
▲FDA ApprovalPalbociclibApprovedFDA Decision
FDA approves IBRANCE regimen for HR+, HER2+ metastatic breast cancer frontline maintenance
HR+, HER2+ metastatic breast cancer frontline maintenancesource ↗
●PublicationPresentation
Landmark publication demonstrating clinical PK predictions using multi-tissue chip platform
◆Topline Readoutsigvotatug vedotinClinical Data
Topline Phase 3 results for Sigvotatug Vedotin
previously treated metastatic non-squamous non-small cell lung cancersource ↗
▲Label ExpansionHYMPAVZIApprovedFDA Decision
FDA approves expanded indication for HYMPAVZI to include hemophilia A or B patients with inhibitors and pediatric patients
hemophilia A or B with inhibitors (12+ years) and pediatric (6-11 years) with or without inhibitorssource ↗
▲Topline ReadoutBerobenatideClinical Data
Phase 2b topline results for Berobenatide in obesity
obesitysource ↗
◆Oral PresentationPF'3944Presentation
Detailed results from VESPER-3 to be presented at ADA 86th Scientific Sessions
obesity or overweight without type 2 diabetessource ↗
◆Oral PresentationTUKYSAApprovedPresentation
Efficacy and safety of tucatinib plus trastuzumab and pertuzumab as maintenance therapy by subgroups
HER2+ metastatic breast cancersource ↗
▲Oral PresentationTALZENNAApprovedPresentation
Late-breaking oral presentation of TALAPRO-3 results at ASCO 2026
metastatic castration-sensitive prostate cancer (mCSPC) with HRR gene mutationssource ↗
▲Primary Endpoint MetTALZENNAApprovedClinical Data
TALAPRO-3 met primary endpoint of rPFS
metastatic castration-sensitive prostate cancer (mCSPC) with HRR gene mutationssource ↗
Past FDA Catalysts and PDUFA Decisions
How PFE actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-26 | TALZENNA plus XTANDI (talazoparib + enzalutamide) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
113
Drugs Scored
rNPV / MCap
Top Drug
Top 1%
Large Pharma(rank 1 of 657)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q))
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Eliquis | |||
| Vyndaqel | |||
| Prevnar family | |||
| Ibrance | |||
| Comirnaty | |||
| Padcev | |||
| Xtandi | |||
| Paxlovid, EUA-Labeled | |||
| Nurtec ODT/Vydura | |||
| Lorbrena | |||
| Abrysvo | |||
| Xeljanz |
Top 12 of 30 product lines shown.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ibuzatrelvir Small moleculeNCT06679140 | COVID-19 SARS-CoV-2 Infection | Phase 3 | RECRUITING | 2,330 | Feb 12, 2028 | ||||||
| ibuzatrelvir Small moleculeNCT07013474 | COVID-19 Infection | Phase 3 | RECRUITING | 300 | Feb 5, 2028 | ||||||
| tilrekimig and rHuPH20 Small moleculeNCT07765888 | Atopic Dermatitis | Phase 3 | RECRUITING | 1,750 | Jun 2, 2028 | ||||||
| tilrekimig and rHuPH20 Small moleculeNCT07772921 | Asthma | Phase 3 | RECRUITING | 2,200 | Aug 24, 2029 | ||||||
| tilrekimig and rHuPH20 Small moleculeNCT07839884 | Moderate to Severe Chronic Obstructive Pulmonary Disease | Phase 3 | NOT YET_RECRUITING | 1,360 | May 12, 2034 | ||||||
| PF-07275315 Small moleculeNCT05995964 | Atopic Dermatitis | Phase 2 | ACTIVE NOT_RECRUITING | 507 | Apr 1, 2027 | ||||||
| PF-07275315 Small moleculeNCT07363694 | Moderate to Severe Chronic Obstructive Pulmonary Disease | Phase 2 | RECRUITING | 1,156 | Jan 16, 2031 | ||||||
| PF-07275315 Small moleculeNCT06977581 | Asthma | Phase 2 | RECRUITING | 252 | May 31, 2027 | ||||||
| Fidanacogene elaparvovec Gene therapyNCT03861273 | Hemophilia B | Phase 3 | ACTIVE NOT_RECRUITING | 51 | Feb 25, 2028 | ||||||
| sigvotatug vedotin ADCNCT06758401 | Non-Small Cell Lung Cancer | Phase 3 | RECRUITING | 714 | Mar 1, 2029 | ||||||
| sigvotatug vedotin ADCNCT06012435 | Carcinoma, Non-Small Cell Lung | Phase 3 | ACTIVE NOT_RECRUITING | 1,774 | May 17, 2028 | ||||||
| PF-08634404 Monoclonal antibodyNCT07222566 | Advanced Non-Small Cell Lung Cancer | Phase 3 | RECRUITING | 1,410 | Aug 26, 2032 | ||||||
| PF-08634404 Monoclonal antibodyNCT07578649 | Endometrial Neoplasms | Phase 3 | NOT YET_RECRUITING | 600 | Jan 30, 2031 | ||||||
| PF-08634404 Small moleculeNCT07222800 | Intestinal Neoplasms | Phase 3 | RECRUITING | 800 | Aug 17, 2031 | ||||||
| PF-08634404 Monoclonal antibodyNCT07392892 | Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma | Phase 2 | RECRUITING | 840 | Jul 21, 2032 | ||||||
| PF-08634404 Small moleculeNCT07226999 | Small Cell Lung Cancer | Phase 2 | RECRUITING | 590 | Mar 11, 2034 | ||||||
| PF-08634404 Monoclonal antibodyNCT07489066 | Carcinoma | Phase 2 | RECRUITING | 120 | Jul 30, 2031 | ||||||
| PF-08634404 Monoclonal antibodyNCT07227298 | Advanced/Metastatic Non-Small Cell Lung Cancer | Phase 1 | RECRUITING | 162 | Aug 23, 2033 | ||||||
| PF-08634404 Monoclonal antibodyNCT07227012 | Carcinoma, Hepatocellular | Phase 1 | RECRUITING | 138 | Oct 17, 2028 | ||||||
| PF-08634404 Monoclonal antibodyNCT07421700 | Urothelial Cancer | Phase 1 | RECRUITING | 132 | Sep 25, 2028 | ||||||
| PF-08634404 Small moleculeNCT07227415 | Carcinoma, Renal Cell | Phase 1 | RECRUITING | 224 | Nov 1, 2028 | ||||||
| PF-08046054 Small moleculeNCT07144280 | Non-small Cell Carcinoma | Phase 3 | RECRUITING | 680 | Mar 10, 2032 | ||||||
| PF-08046054 Small moleculeNCT05208762 | Carcinoma, Non-Small-Cell Lung | Phase 1 | RECRUITING | 714 | Jan 4, 2029 | ||||||
| PF-07220060 Small moleculeNCT07890597 | Early Breast Cancer | Phase 3 | NOT YET_RECRUITING | 3,800 | Aug 20, 2042 | ||||||
| PF-07220060 Small moleculeNCT05262400 | Breast Cancer | Phase 3 | ACTIVE NOT_RECRUITING | 1,391 | Feb 26, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every PFE program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| PF-07872412 | pneumococcal disease | Phase 2 | 2026-10-24 | strong immune responses across all 25 serotypes in infantsRead More | Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| BOURLA ALBERTDirector, Officer (Chairman & CEO) | Buy | 38,000 429,173 held | $26.34 | 08/12/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PFE
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PROSIGHT MANAGEMENT, LP | 0.6 % (-64.7 %) | 3.26 M | 135.37 K | -37.04% ( -79.63 K) |
PFE Institutional Ownership Trends
PFE Short Interest
Shares sold short, counted twice a month.
2.64%
Short % of Float
of tradable shares sold short
150.2M
Shares Sold Short
-3.2% vs prior count
4.4 Moderate
Days to Cover
trading days of normal volume to buy every short share back
34.0M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-30 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PFE ranks across every disease it competes in
Competitive Position is a premium feature
See how PFE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPFE News
PFE▼ -0.9%today
Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting
Pfizer announced FDA approval for TALZENNA in combination with XTANDI for treating men with HRR gene-mutated metastatic prostate cancer. This approval is based on Phase 3 TALAPRO-3 data, demonstrating a 52% reduction in the risk of radiographic progression or death. The combination therapy is now available earlier in the treatment course, potentially benefiting more patients.
Read more →PFE▼ -0.9%today
Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026
Pfizer's investigational 25-valent pneumococcal conjugate vaccine, PF-07872412, demonstrated strong immune responses in infants during a Phase 2 study. The vaccine showed safety comparable to PREVNAR 20 and elicited robust responses against all 25 serotypes, including five new ones. These results support ongoing Phase 3 trials aimed at enhancing protection against invasive pneumococcal disease in children.
Read more →PFEPfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026
Pfizer will present data from over 50 research abstracts at IDWeek 2026, focusing on advancements in infectious disease vaccines, including pneumococcal and Lyme disease vaccines. Key highlights include promising results from Phase 2 and Phase 3 studies on next-generation vaccines. The company emphasizes its commitment to addressing urgent public health challenges through innovative vaccine development.
Read more →PFEEnodia Therapeutics Announces Research Collaboration and License Agreement with Pfizer to Develop Sec61-Targeting Small Molecules
Enodia Therapeutics has entered a research collaboration and license agreement with Pfizer to develop Sec61 inhibitors. This partnership aims to leverage Enodia's proprietary platform for discovering small-molecule therapeutics that inhibit disease-driving proteins while preserving essential functions. Enodia will handle discovery activities, with Pfizer taking over clinical and commercial responsibilities post-collaboration. The agreement could be worth over $500 million.
Read more →PFEPfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer
Pfizer has received FDA approval for TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab. This approval allows the drug to be used as a maintenance treatment for adults with unresectable locally advanced or metastatic HER2+ breast cancer following induction therapy. This marks a significant advancement in treatment options for patients at an earlier stage of metastatic disease.
Read more →PFEPfizer Declares Fourth-Quarter 2026 Dividend
Pfizer Inc. has declared a $0.43 dividend for the fourth quarter of 2026, payable on December 7, 2026. This decision reflects the company's ongoing commitment to its capital allocation strategy, aiming to maintain and grow dividends over time. The upcoming dividend will be the 352nd consecutive payment to shareholders.
Read more →PFEPfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo
Pfizer Inc. presented positive results from two Phase 3 trials for LITFULO (ritlecitinib), demonstrating significant improvements in facial and total body repigmentation in patients with nonsegmental vitiligo. The trials, TRANQUILLO 2 and TRANQUILLO, showed that both 100 mg and 50 mg dosages outperformed placebo. Patient-reported outcomes further supported these findings, indicating reduced disease severity.
Read more →PFEPfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study
Pfizer presented positive results from a Phase 2 study of tilrekimig for atopic dermatitis. The study achieved its primary endpoint, showing a significant increase in skin clearance among participants. This was measured by the Eczema Area and Severity Index at Week 16, indicating promising efficacy for the treatment.
Read more →PFEProfessor Bill Sessa, Former Chief Scientific Officer of Internal Medicine at Pfizer, Appointed Chair of Isomab's Scientific Advisory Board
Isomab Ltd has appointed Professor Bill Sessa as Chair of its Scientific Advisory Board. He will lead a team of distinguished vascular biologists as the company advances its first-in-class anti-VEGF-A165b antibody, ISM-001, towards clinical trials for chronic angina. This strategic move aims to enhance the development of novel therapies for patients with cardiovascular diseases.
Read more →PFEPfizer Advances Today’s Cancer Care and Tomorrow's Potential Breakthroughs at ESMO
Pfizer Inc. will present 45 research abstracts at the upcoming ESMO Congress in Madrid. The presentations will include 11 oral presentations highlighting advancements in cancer treatments, particularly in breast, genitourinary, and lung cancers. This event underscores Pfizer's commitment to enhancing cancer care and exploring future breakthroughs.
Read more →PFEPfizer Invites Public to View and Listen to Webcast of November 3 Conference Call with Analysts
Pfizer Inc. has announced a conference call scheduled for November 3, 2026, at 10:00 a.m. EST. The call aims to update investors on the company's third quarter performance. Participants can access the webcast and the performance report through Pfizer's investor website.
Read more →PFEHealth Canada Authorizes Pfizer and BioNTech's Omicron XFG-Adapted COVID-19 Vaccine
Health Canada has authorized Pfizer and BioNTech's updated COMIRNATY vaccine for the 2026-2027 season, specifically targeting the Omicron XFG variant. This approval is based on extensive clinical and real-world data demonstrating the vaccine's safety and effectiveness. The vaccine will be available through various channels, ensuring equitable access across Canada.
Read more →PFEPfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. is inviting the public and investors to listen to a webcast featuring Alexandre de Germay, the Chief International Commercial Officer, at the J.P. Morgan U.S. All Stars 2026 Conference. The event is scheduled for September 22, 2026, at 11:50 a.m. BST. Details for accessing the webcast can be found on Pfizer's investor website.
Read more →PFEPfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
Pfizer and BioNTech have received FDA approval for their 2026-2027 COVID-19 vaccine, which targets the XFG variant. The vaccine is intended for adults aged 65 and older, as well as younger individuals with underlying health conditions. Shipping of the vaccine will commence immediately to ensure timely access. The approval is based on comprehensive data demonstrating the vaccine's effectiveness against various SARS-CoV-2 variants.
Read more →PFELegal Bay Pre-Settlement Funding Reports Pfizer Agrees to Settle Depo-Provera Birth Control Litigation
Pfizer has agreed to a settlement program to resolve a substantial number of lawsuits alleging that Depo-Provera caused intracranial meningiomas. Legal Bay estimates that around 5,000 claims could settle for over $1.2 billion. The financial terms remain confidential, and actual compensation will depend on various factors. The settlement is seen as a significant development for affected claimants.
Read more →PFEPfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
Pfizer and Valneva announced that the European Medicines Agency has validated their Marketing Authorization Application for PF-07307405, a Lyme disease vaccine candidate. This application is based on positive results from the Phase 3 VALOR trial, which demonstrated over 70% efficacy. The vaccine was well tolerated, with no safety issues reported, marking a significant step in addressing Lyme disease in Europe.
Read more →PFEPfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance
Pfizer Inc. reported its second-quarter financial results for 2026, showcasing a strong performance. The company raised its full-year revenue guidance by $500 million at the midpoint while reaffirming its adjusted diluted EPS guidance. CEO Dr. Albert Bourla highlighted the company's commitment to delivering on financial expectations.
Read more →PFEPfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo
Pfizer has reported positive topline results from two Phase 3 trials of LITFULO for treating nonsegmental vitiligo. The trials assessed the drug's efficacy and safety in patients with varying disease severity. Both studies showed significant results for the 50 and 100 milligram doses, indicating a promising treatment option.
Read more →About Pfizer, Inc.
Headquarters66 HUDSON BOULEVARD EAST, NEW YORK, NY, 10001-2192
BIOPHARMAWATCH ELITE PLUS
Trade the next PFE catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime